ThePharm SRL
2.8 FTEThe score of ThePharm shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -36 % Total assets -24 % Headcount (avg FTE) +22 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
ThePharm's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 112,397 € | ||||
| Equity | 268,374 € | ||||
| Cash | 102,327 € | ||||
| EBITDA | 241,966 € | ||||
| Total assets | 593,897 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Jul 2026
- Year ended 31 Dec 2024filed on 27 May 2025
- Year ended 31 Dec 2023filed on 22 Mar 2024
- Year ended 31 Dec 2022filed on 23 Jun 2023
- Year ended 31 Dec 2021filed on 04 Jul 2022
ThePharm's financial analysis
- Solvency45.2%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of ThePharm
ThePharm's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0403.812.681
- VAT number
- BE0403812681
- Peppol
- Registered · 0208:0403812681 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 01 Jan 1968
- Registered office
- 2060 Antwerp
- Size
- Micro · 2.8 FTE
- Latest accounts
- 2025 · filed on 30 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
ThePharm (SRL) has been based in Antwerp since 1968, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 112,397 € and equity of 268,374 €; its revenue is not published. With 2.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 45.2%, above the median of its sector (44.2%).
Companies similar to ThePharm
Companies in the same business, of comparable size and area, outside its group.
- Apotheek VAN Ghyseghem Retail sale of pharmaceutical products Antwerp · balance sheet 555,938 €
- Humbeek Pharma Retail sale of pharmaceutical products Grimbergen · balance sheet 653,604 €
- Apoteek DE Smedt Retail sale of pharmaceutical products Asse · balance sheet 343,684 €
- LA Pharmacie DU Parc Retail sale of pharmaceutical products Grez-Doiceau · balance sheet 210,632 €
- Smets Pharma Retail sale of pharmaceutical products Lier · balance sheet 452,862 €
- Coop-Apotheken Retail sale of pharmaceutical products Ghent · balance sheet €31.2m
- ELA Services Retail sale of pharmaceutical products Uccle · balance sheet 920,384 €
- Lynapharma Retail sale of pharmaceutical products Saint-Gilles · balance sheet 177,178 €
Frequently asked questions about ThePharm
What is the revenue of ThePharm?
ThePharm files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of ThePharm?
In Belgium, the VAT number is the company number prefixed with BE: BE0403812681 for ThePharm, if the company is VAT-registered. Its company number (CBE) is 0403.812.681.
Where is the registered office of ThePharm?
According to the CBE register, the registered office of ThePharm is in 2060 Antwerp.
What is the equity of ThePharm?
At the close of the 2025 financial year, the equity of ThePharm amounts to 268,374 €, a solvency of 45.2% of total assets.
How many people work at ThePharm?
2.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages ThePharm?
The register lists 2 active mandates at ThePharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of ThePharm
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →